Star Imaging IPO is a book-built issue aiming to raise ₹69.47 crore. It comprises a fresh issue of 39 lakh equity shares aggregating to ₹55.66 crore and an offer for sale of 10 lakh equity shares amounting to ₹13.80 crore. The bidding window was open from August 8, 2025, to August 12, 2025, with the IPO allotment to be finalised on August 13, 2025. Star Imaging is scheduled to list on BSE SME on August 18, 2025.
The IPO was priced at ₹135-₹142 per share with a lot size of 2,000 shares. The public issue received bids for 1,76,17,000 shares against 31,08,000 shares available, resulting in an overall subscription of 5.67 times. QIBs led the response, subscribing 12.85 times their quota, followed by NIIs at 4.38 times and retail investors at 2.32 times.
Star Imaging’s ₹69.47 crore IPO, priced at ₹135-₹142 per share, was subscribed 5.67 times overall. The IPO includes a fresh issue of 39 lakh equity shares aggregating to ₹55.66 crore and an offer for sale of 10 lakh equity shares amounting to ₹13.80 crore. Bidding took place from August 8 to August 12, 2025, with the Star Imaging IPO allotment status on August 13, 2025. Retail investors subscribed 2.32 times and NIIs 4.38 times. Listing is expected on August 18, 2025.
The table below breaks down the Star Imaging share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| Market Maker Shares Offered | 4,80,000 (9.81%) |
| QIB Shares Offered | 21,75,000 (44.46%) |
| − Anchor Investor Shares Offered | 13,04,000 (26.66%) |
| − QIB (Ex. Anchor) Shares Offered | 8,71,000 (17.80%) |
| NII (HNI) Shares Offered | 6,57,000 (13.43%) |
| − bNII > ₹10L | 4,38,000 (8.95%) |
| − sNII < ₹10L | 2,19,000 (4.48%) |
| Retail Shares Offered | 15,28,000 (31.23%) |
| Employee Shares Offered | 52,000 (1.06%) |
| Total Shares Offered | 48,92,000 (100.00%) |
Data Source: NSE
| Category | Subscription (times) |
| Qualified Institutional Buyers | 12.85 |
| Non-Institutional Investors | 4.38 |
| Retail Individual Investors | 2.32 |
| Total shares | 5.67 |
Note: The subscription details are as of August 12, 2025
Incorporated in 2004, Star Imaging and Path Lab Limited is a healthcare company specialising in diagnostic services across a wide range of medical tests. The company offers imaging services such as X-rays, ultrasounds, CT scans, MRIs, and laboratory tests including blood, urine, and other specialised diagnostics. Its operations focus on delivering accurate and timely results to support effective diagnosis and treatment.
The company uses advanced technology and employs experienced medical professionals to maintain high-quality standards in service delivery. Its facilities are equipped to handle both routine and specialised testing, ensuring comprehensive coverage for patient needs. Star Imaging serves individual patients as well as healthcare institutions, building strong relationships with both segments.
Its service portfolio covers radiology, including digital X-ray, mammography, CT scans, and 4D & 5D ultrasound services; pathology, including haematology, microbiology, PCR (polymerase chain reaction), and histopathology; and diagnostics, offering routine and special testing. As of September 30, 2024, the company employed 209 full-time staff, including executive directors.
Star Imaging is promoted by Mr. Pawan Gupta and Ms. Chhaya Gupta, who held 100% of the company’s shares before the IPO and will hold 71.92% post-issue. The promoters’ leadership has been instrumental in driving the company’s growth and maintaining its reputation in the highly competitive and fragmented diagnostics industry.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Aug 12, 2025, 11:42 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
